Pancreatic Cancer Research

ResearcherMichael E. DeBakey VA Medical CenterActive in the last 2 years

Nader Nabile Massarweh

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-7891-4134; OpenAlex author ID A5017667495. Sources: OpenAlex.

Their work

Papers
12 (first author 3, last author 6)
Trials
0
Grants
0
Labs led
2
Collaborators
49
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: 2 papers · 2018: none · 2019: 2 papers · 2020: 1 paper · 2021: 2 papers · 2022: 1 paper · 2023: 2 papers · 2024: none · 2025: 1 paper

Papers 12

  1. Best Practices for Delivering Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2024.5191↗
  2. Adjuvant Therapy for Pancreatic Adenocarcinoma-Leaving No Rock Unturned. Last author DOI 10.1001/jamaoncol.2022.5786↗
  3. Volume-Outcome for Pancreatic Cancer: Finally Getting Under the Hood. First author DOI 10.1245/s10434-022-12944-9↗
  4. Bayesian Approach to Understand the Association Between Treatment Down-staging and Survival for Patients With Pancreatic Adenocarcinoma. Last author DOI 10.1097/sla.0000000000005249↗
  5. Comparative Effectiveness of Neoadjuvant Therapy and Upfront Resection for Patients with Resectable Pancreatic Adenocarcinoma: An Instrumental Variable Analysi… Last author DOI 10.1245/s10434-020-09327-3↗
  6. ASO Author Reflections: Multimodality Therapy for Patients with Pancreatic Cancer: Neoadjuvant Therapy for All? First author DOI 10.1245/s10434-020-09376-8↗
  7. Neoadjuvant Treatment for Patients With Localized Pancreatic Adenocarcinoma: Are We There Yet? Last author DOI 10.1001/jamaoncol.2020.0562↗
  8. Understaging of clinical stage I pancreatic cancer and the impact of multimodality therapy. Last author DOI 10.1016/j.surg.2018.08.003↗
  9. Nodal downstaging as a treatment goal for node-positive pancreatic cancer. First author DOI 10.1016/j.surg.2018.12.009↗
  10. Value of lymph node positivity in treatment planning for early stage pancreatic cancer. Last author DOI 10.1016/j.surg.2017.05.003↗
  11. Nutritional and Metabolic Derangements in Pancreatic Cancer and Pancreatic Resection. Co-author DOI 10.3390/nu9030243↗
  12. Race does not impact pancreatic cancer treatment and survival in an equal access federal health care system. Co-author DOI 10.1245/s10434-013-3130-3↗

Closest collaborators

The 25 strongest of 49 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hop S. Tran Cao · 7 shared papers, 2017–2022 · strength 0.92
  2. Wilson Luiz da Costa · 4 shared papers, 2020–2022 · strength 0.85
  3. Meredith C. Mason · 2 shared papers, 2023 · strength 0.69
  4. Maria Citarella Russell · 1 shared paper, 2023 · strength 0.31
  5. Matthew H. G. Katz · 3 shared papers, 2013–2025 · strength 0.26
  6. Eric Jay Silberfein · 3 shared papers, 2017–2019 · strength 0.22
  7. George Van Buren · 3 shared papers, 2017–2019 · strength 0.22
  8. William E. Fisher · 2 shared papers, 2017–2019 · strength 0.16
  9. Omar Barakat · 2 shared papers, 2017–2019 · strength 0.16
  10. Davendra P. S. Sohal · 1 shared paper, 2025 · strength 0.15
  11. Andrew H. Ko · 1 shared paper, 2025 · strength 0.15
  12. Alok A. Khorana · 1 shared paper, 2025 · strength 0.15
  13. Steve Walston · 1 shared paper, 2025 · strength 0.15
  14. Cristina R. Ferrone · 1 shared paper, 2025 · strength 0.15
  15. P. A. Philip · 1 shared paper, 2025 · strength 0.15
  16. Melissa Ellen Hogg · 1 shared paper, 2025 · strength 0.15
  17. Matthew J. Arango · 1 shared paper, 2025 · strength 0.15
  18. Susan Elaine Bates · 1 shared paper, 2025 · strength 0.15
  19. William Adrian Hall · 1 shared paper, 2025 · strength 0.15
  20. Maria Q. B. Petzel · 1 shared paper, 2025 · strength 0.15
  21. David A. Kooby · 1 shared paper, 2025 · strength 0.15
  22. Marsha Reyngold · 1 shared paper, 2025 · strength 0.15
  23. Mahvish Muzaffar · 1 shared paper, 2025 · strength 0.15
  24. Karyn A. Goodman · 1 shared paper, 2025 · strength 0.15
  25. Efrat Dotan · 1 shared paper, 2025 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.